Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting

Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better in clinical study. Alcon is the first refractive laser manufacturer to receive FDA approval for a topography-guided LASIK procedure   -   Alcon to further showcase new data in glaucoma treatments, cataract as well as refractive surgery procedures using Wavelight technology                Alcon, the global leader in eye care and a division of Novartis, will introduce Contoura Vision, the latest advancement in its WaveLight refractive portfolio during the annual meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, November 14-17, 2015. Alcon will also present new research findings in glaucoma, cataract and refractive surgical procedures at AAO. Building on its broad portfolio of ophthalmic surgical innovations, Contoura Vision is a topography-guided LASIK treatment designed to provide surgeons the ability to perform more personalized laser procedures for patients with nearsightedness, or nearsightedness with astigmatism, based on the unique corneal topography of each eye. In 2014, more than 630,000 LASIK procedures were performed in the US alone. "We are pleased to provide surgeons with a technology that has been shown to deliver visual acuity better than glasses or lenses for nearly one-third of patient eyes in a clinical trial setting," said Franck Leveiller, Head of Research & Development for Alcon's Surgical Franchise.